Genmab A/S (NASDAQ:GMAB) Lowered to "Hold" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Genmab A/S (NASDAQ:GMAB - Free Report) from a buy rating to a hold rating in a report released on Friday morning.

GMAB has been the topic of several other research reports. HC Wainwright reissued a "buy" rating and set a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Price Performance

Shares of NASDAQ GMAB traded up $0.05 during midday trading on Friday, hitting $22.25. 790,871 shares of the company's stock were exchanged, compared to its average volume of 1,158,024. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.56. The firm has a market cap of $14.27 billion, a P/E ratio of 12.79, a PEG ratio of 2.65 and a beta of 0.96. The stock's 50 day moving average price is $20.14 and its 200-day moving average price is $20.67.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. On average, analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Several large investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its stake in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Headlands Technologies LLC increased its stake in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after acquiring an additional 1,464 shares during the last quarter. Lindbrook Capital LLC increased its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after acquiring an additional 1,070 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.